Connect with us


Biotech On Track To Develop Bio-Synthetic Cannabinoids



InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF) released news Sept 25, 2017 revealing that the company had made breakthroughs in the scale-up and commercialization of the biosynthesis process for cannabinoid production.

IN/IMLFF noted that it can selectively produce all four “gateway” cannabinoids using genetically engineered microorganisms.   InMed President, Eric Adams, explained that through synthesis, IN/IMLFF could produce a variety of cannabinoids economically, which opens the door for new products.

Adams further noted that InMed was “dedicating substantial resources” to the commercialization of biosynthetic cannabinoid products.

Financials Trend began covering InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF) following its news on Sept 19, 2017, after announcing the filing of patents on biosynthesis of cannabinoids.  At the time we published that story, shares of InMed Pharmaceuticals rose 7% to $0.36.  Now, IN/IMLFF is trading at nearly $0.45.

We noted in our IN/IMLFF story that it was [BIG NEWS to the scientific community], but Mr. Adams clarified that further in yesterday’s press release when he explained how some extracts from marijuana are expensive to produce but through biosynthesis synthetic cannabinoids are just the opposite.

“The biosynthesis process opens up access to drug discovery and therapeutic use of all 90+ cannabinoids, most of which occur in only trace amounts in the plant and cannot be extracted in an economical fashion,” said Adams.

InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF) shares are trading up over 100% since Financials Trend first covered the company.  In that first article, we called InMed Pharmaceutical a “Five Bagger”, noting its gateway price of $0.21 at the time IN/IMLFF announced its patent applications and so far, it’s not disappointing our readers.  Our outlook hasn’t changed, yet we still stress patience in following IN/IMLFF progress.



Insys Therapeutics Inc (NASDAQ:INSY) Issues An Update on CBD Pharmaceuticals and Spray Technology Products




Insys Therapeutics Inc (NASDAQ:INSY) has issued an update on the naloxone nasal and epinephrine sprays and CBD oral solutions. CEO and President of Insys Therapeutics, Saeed Motahari said the company is focusing on novel drug delivery systems and pharmaceutical grade cannabinoids to drive the growth going forward. It is moving away from opioids. The company is transforming its business strategy to include patient-centric formulations over the past one year. Going forward,  Insys Therapeutics is preparing to submit 6 innovative drug applications in the next 3 years. The company is scheduling two of them in 2019.

An update on the Opioid Related Assets

As per the announced plans,  Insys Therapeutics is scheduling the alternative review of the opioid related assets. As of now, nine firms have entered into a pact with  Insys Therapeutics and are reviewing the confidential information. The company will release an update on this aspect in early 2019.

An Update on the Lifesaving Products

Insys Therapeutics is in the advanced stages of developing the lifesaving investigational products that are based on spray technologies. Its lifesaving products in development include epinephrine nasal spray for anaphylaxis and naloxone nasal spray for the opioid overdose.

The company is also focusing on cannabinoids like CBD oral solution targeting the child absence epilepsy treatment (phase 2), Prader Willi Syndrome (phase 2), infantile spasms (phase 3), and dronabinol inhalation to treat a variety of conditions such as anorexia in patients suffering from cancer.

Insys Therapeutics is conducting a non-clinical toxicity study on naloxone nasal spray and expects to announce the results in March 2019. The company has set the timeframe for the NDA submission in Q1 2019.

Epinephrine nasal spray, which is intended for needle-free delivery, is a substitute to the intramuscular injection. According to the study, it is readily absorbed via the nasal mucosa. The company has obtained FDA nod for fast track designation for the drug in August 2018. It has also provided specific guidelines for filing requirement and clinical development. Insys Therapeutics is optimistic to complete the filing requirements for epinephrine NDA in Q4, 2019. It is subject to successful completion of PK study.

The company has successfully completed a proof of concept study on dronabinol inhalation in September 2018. Insys Therapeutics will arrange a meeting with clinical experts in Q1 2019 to discuss further development for this investigational formulation.

Insys Therapeutics Signs a Pact with Lunatus for Commercializing SUBSYS

Insys Therapeutics has signed a definitive accord with Lunatus for commercializing Subsys in 8 nations in the Middle East. Following the deal, Lunatus will act as an authorized agent and licensee in the UAE, Lebanon, Kuwait, Jordan, Saudi Arabia, Qatar, Oman, and Bahrain.

Continue Reading


International Consolidated Inc (OTCMKTS:INCC) Pronounces A $5 Million Dollar Institutional Offer



International Consolidated Inc (OTCMKTS:INCC) is quite pleased to make the announcement that obtained an institutional offer worth $5 million dollars from the IFG Opportunity Fund LLC. According to a person well conversant with the matter, it happened prior to the company becoming fully reporting.

The business guru is making plans to move ahead and execute its business plan and it is crucial to mention the point that the undertaking served them with about three 3 additional options for funding.

The company’s take on business operations

It was way back in 2004 that the IFG Opportunity Fund, LLC began as a private equity fund set up to make investments in the series of the small growth companies via the PIPE’s which are fundamentally private investments in public equities.

They invest in their own capital and that of course indicates more flexibility as well as a greater competitive advantage at a time when business dynamics tend to be shifting quite fast. Competitive pricing is a point that the business giant takes with much seriousness and market observers have termed that a great way to move about business.

The water-soluble CBD oil super food and expert strategies

The water-soluble CBD oil super food and wellness drinks that are being introduced by BluDog Products are easily absorbed. And they are the perfect alternative for over-the-counter therapeutic option that helps promote well being and relaxation.

Asides from that they play a significant role helping relieve post-sports inflammation not forgetting that the CBD products naturally interact with the anti-inflammatory system of the body and there are no associated side effects.

The Managing Member of BluDog Products LLC Antonio Uccello while moving out of a business conference addressed news reporters telling them that as a company they were quite pleased about getting to the point of providing high quality BluDog Products.

Much has been happening in the recent years, one of the things being the acquisition of the American Nutritional Products Inc. Several market analysts have said that the company is placing itself on the right path in the quest to achieve monumental success in a market characterized with stiff competition.

Continue Reading


Premier Biomedical Inc (OTCMKTS:BIEI) Searches For Development Partner To Develop Patent Pending Technology



Premier Biomedical Inc (OTCMKTS:BIEI) reported that they are actively looking for an associate to advance their patented extracorporeal treatment procedure in together with their patent pending process for treating ailments through the application of lasers.

The buzz

The methodology uses the concept of curing the blood outside the human body in a continuous flow procedure, together with an emissive energy means, such as a laser, to destroy directed antigens in the blood, before returning the blood to the person. The firm has exceptional privileges to three dispensed patents, one provisional patent application and six pending applications, all related to unique treatments for cancer as well as extracorporeal treatments for different life-threatening ailments.

Dr. Felder, the Inventor of the underlying technologies, expressed that the application of lasers in conjunction with their extracorporeal treatment procedure is a thrilling concept, as it should eliminate any infectious ailment, without the probability of pathogen resistance, or the action of side effects from the therapy. It also has the prospect for being an efficacious and inexpensive treatment for septicemia — a major cause of death globally.

William A. Hartman, the CEO and President of Premier Biomedical, expressed that they consider this combination of their patented extracorporeal treatment procedure with their patent awaiting emissive energy ablation of directed antigens could pave a complete new chapter in the means diseases are cured. The efficacy and safety of treatment protocols for a broad range of ailments could be considerably improved.

Premier Biomedical marks as a research-based publicly traded firm that plans to develop and discover medical treatments for a broad range of ailments in humans. The company has obtained, through different license agreements, the know-how behind three allowed US Patents, several pending provisional patents, as well as a ‘PCT’ Europe National Patent. Premier Biomedical was established back in 2010.

Continue Reading

Trading Symbol


The Next Big Global Cannabis Trade


Business22 hours ago

Green Organic Dutchman Holdings (OTCMKTS:TGODF) To Review Financing Alternatives For Construction Purposes

Post Views: 111 Green Organic Dutchman Holdings (OTCMKTS:TGODF) has, over the years, been focusing on the production of premium organic...

Business22 hours ago

HEXO (OTCMKTS:HYYWF) Expects To Post Net Revenues Of $16.5 Million in Q4 2019 And $48.5 Million For FY 2019

Post Views: 107 HEXO (OTCMKTS:HYYWF) expects to post net revenues of up to $16.5 million in Q4 2019. The company...

Business4 days ago

LeafBuyer Technologies Inc. (OTCMKT:LBUY) Reports 59% YoY Growth In Revenue Following Optimization Of Its Platforms

Post Views: 204 LeafBuyer Technologies Inc. (OTCMKT:LBUY) has announced that its annual revenue for FY 2019 grew by 59%, reflecting...

Business4 days ago

High Tide Inc. (OTCMKTS:HITIF) Report Impressive Q3 Financial Results with Revenue Growing 281%

Post Views: 168 High Tide Inc. (OTCMKTS:HITIF) has announced an inspiring financial result for its third quarter of 2019. The...

Business5 days ago

Kalytera Therapeutics Inc (OTCMKTS:KALTF) Provides Details About Its Latest Notice Of Allowance

Post Views: 148 Kalytera Therapeutics Inc (OTCMKTS:KALTF) has today revealed details regarding the EU Patent Application Number 14791611.8. According to...

Business5 days ago

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Engages Cellular Biologist David A. Judd In An Interview

Post Views: 752 Pharmacyte Biotech Inc (OTCMKTS:PMCB) uses its live-cell encapsulation technology known as Cell-in-a-Box®  for the treatment of diabetes...

Business6 days ago

CV Sciences Inc (OTCMKTS:CVSI) enters a Distribution Agreement With Harris Teeter

Post Views: 141 CV Sciences Inc (OTCMKTS:CVSI) today announced its business collaboration with Harris Teeter. These two business giants target...

Business6 days ago

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Speaks Out On Its CAUMZ(TM) Kit

Post Views: 158 Tetra Bio Pharma Inc (OTCMKTS:TBPMF) is one of the leaders in the cannabinoid-based therapeutics sector. Some of...

Business7 days ago

Medical Marijuana Inc (OTCMKTS:MJNA) Speaks Out On The European Road To Area Tour

Post Views: 178 Medical Marijuana Inc (OTCMKTS:MJNA) made a mark by becoming the first company to unveil cannabis-derived nutraceutical products....

Business7 days ago

HempAmericana Inc (OTCMKTS:HMPQ) To Unveil Its New Smokable Hemp Flower Product Line

Post Views: 156 HempAmericana Inc (OTCMKTS:HMPQ) will, on November 2019, unveil its new Smokable Hemp Flower product line. The company...

Whats Hot




Trading Symbol


Choom Holdings Inc. CSE: CHOO | OTCQB: CHOOF